StockData
RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31

RELMADA THERAPEUTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.16+0.06 (+1.94%)

Close on Oct 19, 2026

Market cap
$355.11M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 12, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 6, 2026During market hours–$-0.11–
Q1 FY2026
Ended Mar 31, 2026
May 12, 2026During market hours–$-0.22–
Q4 FY2025
Ended Dec 31, 2025
Mar 20, 2026During market hours–$-0.27–
Q3 FY2025
Ended Sep 30, 2025
Nov 13, 2025During market hours–$-0.30–
Q2 FY2025
Ended Jun 30, 2025
Aug 7, 2025During market hours–$-0.30–
Q4 FY2024
Ended Dec 31, 2024
Mar 27, 2025During market hours–$-0.62–
Q4 FY2023
Ended Dec 31, 2023
Mar 19, 2024During market hours–$-0.84–
Q3 FY2023
Ended Sep 30, 2023
Nov 8, 2023During market hours–$-0.73–
Q2 FY2023
Ended Jun 30, 2023
Aug 8, 2023During market hours–$-0.84–
Q1 FY2023
Ended Mar 31, 2023
May 11, 2023During market hours–$-0.87–
Q4 FY2022
Ended Dec 31, 2022
Mar 23, 2023During market hours–$1.28–

Press releases

Announcements Relmada Therapeutics filed with the SEC